MIRATI THERAPEUTICS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1995-12-13
- Employees
- 593
- Market Cap
- -
- Website
- http://www.mirati.com
Clinical Trials
93
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (91 trials with phase data)• Click on a phase to view related trials
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 630
- Registration Number
- NCT06875310
- Locations
- 🇺🇸
Local Institution - 0347, Birmingham, Alabama, United States
🇺🇸Local Institution - 0581, Fullerton, California, United States
🇺🇸Local Institution - 0202, Long Beach, California, United States
Bioequivalence Study Between Adagrasib Reference Tablets and High Drug Load Tablets
- First Posted Date
- 2025-01-30
- Last Posted Date
- 2025-02-28
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT06801418
- Locations
- 🇺🇸
ICON - Lenexa, Lenexa, Kansas, United States
🇺🇸ICON Development Solutions, San Antonio, Texas, United States
🇺🇸ICON - Salt Lake City, Salt Lake City, Utah, United States
A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib
- First Posted Date
- 2023-06-29
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05924152
- Locations
- 🇺🇸
Fortrea Clinical Research Unit Daytona Beach (Labcorp Clinical Research Unit Daytona Beach), Daytona Beach, Florida, United States
A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib
- Conditions
- Healthy Adults
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05868356
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc, Dallas, Texas, United States
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
- Conditions
- Advanced CancerMetastatic CancerMalignant Neoplasm of Lung
- Interventions
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Mirati Therapeutics Inc.
- Target Recruit Count
- 200
- Registration Number
- NCT05853575
- Locations
- 🇺🇸
Providence Medical Foundation - Research, Santa Rosa, California, United States
🇺🇸Local Institution - 104, Chicago, Illinois, United States
🇺🇸Local Institution - 103, Minneapolis, Minnesota, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 10
- Next
News
FDA Grants Accelerated Approval to Adagrasib Plus Cetuximab for KRAS G12C-Mutated Advanced Colorectal Cancer
The FDA has granted accelerated approval to adagrasib plus cetuximab for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer who have received prior chemotherapy.